Free Trial
→ URGENT: If you own a home, please review the map below. (From Paradigm Press) (Ad)tc pixel Free ALDX Stock Alerts

Aldeyra Therapeutics (ALDX) Financials

Aldeyra Therapeutics logo
$0.64 +0.01 (+2.17%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$0.69 +0.04 (+6.87%)
As of 11/13/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Aldeyra Therapeutics

Annual Income Statements for Aldeyra Therapeutics

This table shows Aldeyra Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -12 -19 -22 -39 -61 -38 -58 -62 -38 -56 -34
Consolidated Net Income / (Loss)		 -12 -19 -22 -39 -61 -38 -58 -62 -38 -56 -34
Net Income / (Loss) Continuing Operations		 -12 -19 -22 -39 -61 -38 -58 -62 -38 -56 -34
Total Pre-Tax Income 		-12 -19 -22 -39 -62 -38 -58 -62 -38 -56 -34
Total Operating Income		 -12 -19 -22 -40 -63 -36 -56 -63 -43 -60 -35
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 12 19 22 40 63 36 56 63 43 60 35
Selling, General & Admin Expense		 4.41 5.52 6.19 9.88 12 9.99 11 15 13 12 9.60
Research & Development Expense		 7.57 13 16 30 51 26 45 47 29 48 26
Total Other Income / (Expense), net		 -0.10 -0.00 0.15 0.81 0.94 -1.61 -1.56 0.66 5.25 4.27 1.42
Interest Expense		 0.11 0.11 0.11 0.15 0.60 1.90 1.74 1.69 2.07 1.93 1.91
Interest & Investment Income		 0.01 0.10 0.26 0.95 1.54 0.29 0.19 2.35 7.32 6.19 3.32
Basic Earnings per Share		 ($1.40) ($1.65) ($1.40) ($1.79) ($2.24) ($1.11) ($1.07) ($1.06) ($0.64) ($0.94) ($0.56)
Weighted Average Basic Shares Outstanding		 8.63M 11.35M 15.92M 21.69M 27.11M 33.97M 54.04M 58.41M 58.94M 59.48M 60.06M
Diluted Earnings per Share		 ($1.40) ($1.65) ($1.40) ($1.79) ($2.24) ($1.11) ($1.07) ($1.06) ($0.64) ($0.94) ($0.56)
Weighted Average Diluted Shares Outstanding		 8.63M 11.35M 15.92M 21.69M 27.11M 33.97M 54.04M 58.41M 58.94M 59.48M 60.06M
Weighted Average Basic & Diluted Shares Outstanding		 8.63M 11.35M 15.92M 21.69M 27.11M 33.97M 54.04M 58.58M 58.90M 59.71M 60.18M

Quarterly Income Statements for Aldeyra Therapeutics

This table shows Aldeyra Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -8.08 -17 -15 -16 -9.93 -9.77 -7.69 -6.46 -3.45 -5.45 -3.76
Consolidated Net Income / (Loss)		 -8.08 -17 -15 -16 -9.93 -9.77 -7.69 -6.46 -3.45 -5.45 -3.76
Net Income / (Loss) Continuing Operations		 -8.08 -17 -15 -16 -9.93 -9.77 -7.69 -6.46 -3.45 -5.45 -3.76
Total Pre-Tax Income 		-8.08 -17 -15 -16 -9.93 -9.77 -7.69 -6.46 -3.45 -5.45 -3.76
Total Operating Income		 -9.39 -18 -16 -17 -10 -10 -8.00 -6.67 -3.55 -5.85 -4.14
Total Gross Profit		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses		 9.39 18 16 17 10 10 8.00 6.67 3.55 5.85 4.14
Selling, General & Admin Expense		 3.21 3.04 3.70 1.95 3.00 1.66 2.57 2.36 1.14 2.37 2.30
Research & Development Expense		 6.18 15 12 15 7.42 8.51 5.43 4.30 2.41 3.48 1.84
Total Other Income / (Expense), net		 1.31 1.16 1.02 0.77 0.50 0.40 0.31 0.21 0.09 0.40 0.37
Interest Expense		 0.50 0.48 0.48 0.47 0.48 0.47 0.48 0.48 0.47 0.00 0.00
Interest & Investment Income		 1.81 1.64 1.50 1.24 0.98 0.87 0.79 0.68 0.56 0.40 0.37
Basic Earnings per Share		 ($0.14) ($0.28) ($0.25) ($0.27) ($0.17) ($0.16) ($0.13) ($0.10) ($0.06) ($0.09) ($0.06)
Weighted Average Basic Shares Outstanding		 59.41M 59.41M 59.53M 59.48M 59.89M 60.05M 60.13M 60.06M 60.32M 60.32M 60.35M
Diluted Earnings per Share		 ($0.14) ($0.28) ($0.25) ($0.27) ($0.17) ($0.16) ($0.13) ($0.10) ($0.06) ($0.09) ($0.06)
Weighted Average Diluted Shares Outstanding		 59.41M 59.41M 59.53M 59.48M 59.89M 60.05M 60.13M 60.06M 60.32M 60.32M 60.35M
Weighted Average Basic & Diluted Shares Outstanding		 59.41M 59.42M 59.55M 59.71M 59.90M 59.90M 60.16M 60.18M 60.32M 60.33M 60.36M

Annual Cash Flow Statements for Aldeyra Therapeutics

This table details how cash moves in and out of Aldeyra Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 6.12 -2.63 8.01 27 -2.93 33 152 -85 -1.60 -88 16
Net Cash From Operating Activities		 -9.31 -15 -19 -30 -45 -37 -43 -57 -30 -43 -33
Net Cash From Continuing Operating Activities		 -9.31 -15 -19 -30 -45 -37 -43 -57 -30 -43 -33
Net Income / (Loss) Continuing Operations		 -12 -19 -22 -39 -61 -38 -58 -62 -38 -56 -34
Consolidated Net Income / (Loss)		 -12 -19 -22 -39 -61 -38 -58 -62 -38 -56 -34
Depreciation Expense		 0.02 0.04 0.04 0.07 0.10 0.06 0.26 0.26 0.26 0.25 0.25
Amortization Expense		 0.04 0.29 0.15 -0.18 -0.34 0.47 0.41 0.28 0.34 -1.49 -0.93
Non-Cash Adjustments To Reconcile Net Income		 2.19 2.76 2.71 4.14 15 8.84 7.11 8.29 5.75 7.97 6.36
Changes in Operating Assets and Liabilities, net		 0.54 0.46 0.22 5.00 1.43 -9.31 7.44 -3.44 0.86 5.91 -5.18
Net Cash From Investing Activities		 -13 -0.23 -10 -23 18 29 -0.01 -30 30 -45 48
Net Cash From Continuing Investing Activities		 -13 -0.23 -10 -23 18 29 -0.01 -30 30 -45 48
Purchase of Investments		 -13 -16 -35 -60 -58 -5.78 0.00 -93 0.00 -97 -40
Sale and/or Maturity of Investments		 0.00 16 25 37 76 35 0.00 63 30 52 88
Net Cash From Financing Activities		 28 13 37 81 24 42 194 1.22 -1.27 -0.17 1.12
Net Cash From Continuing Financing Activities		 28 13 37 81 24 42 194 1.22 -1.27 -0.17 1.12
Repayment of Debt		 - - 0.00 -1.40 -0.12 - - 0.00 -1.04 -0.29 0.00
Repurchase of Common Equity		 - - - - - - - - 0.00 -0.27 0.00
Issuance of Common Equity		 - 13 38 82 8.09 41 190 0.10 0.11 0.04 0.02
Other Financing Activities, net		 28 0.00 -0.17 - 1.16 1.06 4.62 1.12 -0.34 0.35 1.10
Cash Interest Paid		 0.07 0.08 0.09 0.09 0.24 1.39 1.34 1.34 1.70 1.75 1.69

Quarterly Cash Flow Statements for Aldeyra Therapeutics

This table details how cash moves in and out of Aldeyra Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents		 -40 -31 -2.91 -14 -4.18 -9.11 18 11 -5.04 -20 -4.11
Net Cash From Operating Activities		 -9.97 -13 -7.97 -12 -12 -8.56 -7.02 -5.30 -5.11 -4.59 -4.12
Net Cash From Continuing Operating Activities		 -9.97 -13 -7.97 -12 -12 -8.56 -7.02 -5.30 -5.11 -4.59 -4.12
Net Income / (Loss) Continuing Operations		 -8.08 -17 -15 -16 -9.93 -9.77 -7.69 -6.46 -3.45 -5.45 -3.76
Consolidated Net Income / (Loss)		 -8.08 -17 -15 -16 -9.93 -9.77 -7.69 -6.46 -3.45 -5.45 -3.76
Depreciation Expense		 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.07 0.07 0.07 0.15
Non-Cash Adjustments To Reconcile Net Income		 1.55 1.94 3.23 1.26 2.49 0.20 2.58 1.09 -0.99 1.64 1.11
Changes in Operating Assets and Liabilities, net		 -3.39 2.11 4.32 2.87 -4.75 1.33 -1.76 0.00 -0.79 -0.85 -1.63
Net Cash From Financing Activities		 0.02 - -0.20 0.01 1.00 - 0.12 - 0.07 -15 0.01
Net Cash From Continuing Financing Activities		 0.02 - -0.20 0.01 1.00 - 0.12 - 0.07 -15 0.01
Issuance of Common Equity		 0.02 - -0.20 0.22 0.02 - - - 0.00 - 0.01

Annual Balance Sheets for Aldeyra Therapeutics

This table presents Aldeyra Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 28 25 44 95 76 83 233 181 148 105 72
Total Current Assets		 28 25 44 95 75 83 233 181 148 104 72
Cash & Equivalents		 15 12 20 47 44 78 230 144 143 55 70
Prepaid Expenses		 0.50 0.22 1.02 1.17 1.80 5.20 2.96 6.72 4.99 2.92 1.74
Plant, Property, & Equipment, net		 0.08 0.06 0.04 0.24 0.15 0.06 0.03 0.02 0.01 0.00 0.00
Total Noncurrent Assets		 0.04 0.00 0.17 0.09 0.20 0.23 0.35 0.25 0.51 0.53 0.28
Other Noncurrent Operating Assets		 0.04 0.00 0.17 0.09 0.20 0.23 0.35 0.25 0.51 0.53 0.28
Total Liabilities & Shareholders' Equity		 28 25 44 95 76 83 233 181 148 105 72
Total Liabilities		 3.33 3.54 4.57 8.47 27 24 27 30 29 34 28
Total Current Liabilities		 2.12 2.30 3.35 8.47 13 12 12 15 22 19 28
Short-Term Debt		 0.08 0.08 0.12 - 0.00 3.66 0.00 0.91 15 0.03 15
Accounts Payable		 0.85 0.28 1.00 3.05 0.81 0.38 1.02 0.13 1.34 0.18 0.16
Accrued Expenses		 1.19 1.95 2.24 5.42 12 8.13 11 14 5.54 12 6.12
Current Deferred Revenue		 - - - - - - - - 0.00 6.00 6.00
Other Current Liabilities		 - - - - 0.23 0.23 0.23 0.25 0.24 0.27 0.28
Total Noncurrent Liabilities		 1.21 1.24 1.22 0.00 15 11 16 15 6.27 15 0.00
Other Noncurrent Operating Liabilities		 - - - - - 0.00 0.13 0.00 6.27 - 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 25 22 40 87 48 60 206 151 120 71 44
Total Preferred & Common Equity		 25 22 40 87 48 60 206 151 120 71 44
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 25 22 40 87 48 60 206 151 120 71 44
Common Stock		 83 99 139 225 247 296 500 508 514 521 528
Retained Earnings		 -59 -77 -100 -139 -199 -237 -295 -357 -394 -450 -484

Quarterly Balance Sheets for Aldeyra Therapeutics

This table presents Aldeyra Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets		 147 141 126 117 93 85 78 66 48 43
Total Current Assets		 147 141 126 117 93 85 77 66 47 43
Cash & Equivalents		 143 102 71 68 50 41 59 65 45 41
Prepaid Expenses		 3.88 7.81 5.32 3.98 2.67 2.64 2.16 1.27 2.29 1.94
Plant, Property, & Equipment, net		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.02
Total Noncurrent Assets		 0.06 0.45 0.39 0.60 0.47 0.40 0.34 0.21 0.14 0.45
Other Noncurrent Operating Assets		 0.06 0.45 0.39 0.60 0.47 0.40 0.34 0.21 0.14 0.45
Total Liabilities & Shareholders' Equity		 147 141 126 117 93 85 78 66 48 43
Total Liabilities		 24 28 28 32 30 30 29 24 9.66 8.16
Total Current Liabilities		 22 22 28 17 14 30 28 24 9.66 7.88
Short-Term Debt		 13 15 15 0.28 0.00 15 15 15 0.00 0.00
Accounts Payable		 0.25 0.28 0.25 0.19 0.35 1.46 0.01 0.14 0.14 0.14
Accrued Expenses		 7.84 5.94 5.84 10 7.68 6.66 7.00 2.67 3.37 1.56
Current Deferred Revenue		 - - 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00
Other Current Liabilities		 0.07 0.25 0.26 0.26 0.26 0.26 0.27 0.21 0.14 0.18
Total Noncurrent Liabilities		 2.66 6.21 0.14 15 15 0.14 0.07 0.00 0.00 0.28
Other Noncurrent Operating Liabilities		 - 6.21 0.14 0.07 0.21 0.14 0.07 0.00 0.00 0.28
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 123 113 98 85 64 55 49 42 38 35
Total Preferred & Common Equity		 123 113 98 85 64 55 49 42 38 35
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 123 113 98 85 64 55 49 42 38 35
Common Stock		 513 516 518 519 524 525 527 530 531 532
Retained Earnings		 -390 -402 -419 -434 -460 -470 -477 -487 -493 -497

Annual Metrics And Ratios for Aldeyra Therapeutics

This table displays calculated financial ratios and metrics derived from Aldeyra Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 9,712,521.00 12,576,326.00 19,117,676.00 26,244,434.00 27,952,937.00 38,820,347.00 58,092,105.00 58,560,078.00 58,822,083.00 - 60,162,773.00
DEI Adjusted Shares Outstanding		 9,712,521.00 12,576,326.00 19,117,676.00 26,244,434.00 27,952,937.00 38,820,347.00 58,092,105.00 58,560,078.00 58,822,083.00 - 60,162,773.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.24 -1.49 -1.17 -1.48 -2.18 -0.97 -0.99 -1.06 -0.64 - -0.56
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -149.09% -53.90% -21.42% -78.50% -59.05% 43.31% -54.77% -11.87% 32.10% -45.43% 41.42%
EBIT Growth		 -142.54% -55.94% -20.28% -76.53% -58.88% 42.26% -54.36% -11.49% 31.73% -40.48% 41.34%
NOPAT Growth		 -64.90% -55.94% -20.28% -76.53% -58.88% 42.26% -54.36% -11.49% 31.73% -40.48% 41.34%
Net Income Growth		 -133.08% -54.67% -19.47% -74.09% -56.39% 38.26% -53.85% -7.35% 39.47% -48.77% 39.40%
EPS Growth		 54.69% -17.86% 15.15% -27.86% -25.14% 50.45% 3.60% 0.93% 39.62% -46.88% 40.43%
Operating Cash Flow Growth		 -94.97% -62.67% -26.90% -55.32% -50.66% 16.65% -13.50% -33.09% 46.46% -42.48% 22.83%
Free Cash Flow Firm Growth		 0.43% -57.86% -24.80% -45.52% -76.97% 18.29% -3.23% -32.04% 34.33% -18.00% 16.04%
Invested Capital Growth		 -43.75% -36.75% -3.22% -247.48% -54.03% 69.73% -162.68% 12.79% -5.68% -91.78% 30.26%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -19.23% -1.29% -51.79% 2.42% -4.22% 6.35% -7.66% 2.65% 15.28% -21.78% 22.34%
EBIT Q/Q Growth		 -19.16% -1.72% -49.91% 2.57% -2.94% 4.23% -7.90% 2.65% 15.08% -21.11% 21.94%
NOPAT Q/Q Growth		 -19.16% -1.72% -49.91% 2.57% -2.94% 4.23% -7.90% 2.65% 15.08% -21.11% 21.94%
Net Income Q/Q Growth		 -18.78% -1.62% -49.44% 3.50% -4.34% 5.89% -9.36% 4.40% 17.84% -24.68% 21.64%
EPS Q/Q Growth		 -172.54% 6.25% -37.25% 16.36% -4.67% 14.62% 1.83% 4.50% 17.95% -25.33% 23.29%
Operating Cash Flow Q/Q Growth		 -17.67% -6.35% -6.12% -10.96% -7.81% 7.20% -8.30% 0.61% 27.89% -40.88% 16.81%
Free Cash Flow Firm Q/Q Growth		 -13.08% -8.19% -33.77% 4.92% -8.59% 6.99% -5.62% -2.28% 23.19% -31.08% 11.70%
Invested Capital Q/Q Growth		 -121.75% -2.77% -197.97% -34.28% 1.39% -58.63% -36.22% -1.01% -87.26% -22.21% 2.88%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 97.89% 98.74% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.84% 100.02% 99.34% 97.97% 98.51% 104.43% 102.77% 98.95% 87.73% 92.90% 95.98%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -77.60% -80.38% -72.95% -61.63% -90.31% -69.81% -43.56% -34.77% -27.73% -58.54% -58.73%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -77.60% -80.38% -72.95% -61.63% -90.31% -69.81% -43.56% -34.77% -27.73% -58.54% -58.73%
Return on Equity Simple (ROE_SIMPLE)		 -48.60% -86.37% -56.41% -44.90% -126.51% -63.11% -28.08% -41.07% -31.34% -78.66% 0.00%
Net Operating Profit after Tax (NOPAT)		 -8.39 -13 -16 -28 -44 -25 -39 -44 -30 -42 -25
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -22.03% -22.49% -20.24% -16.42% -21.88% -19.83% -13.30% -9.74% -5.30% -12.88% -13.00%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -22.20% -48.91% -41.49%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -12 -19 -22 -40 -63 -36 -56 -63 -43 -60 -35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -12 -18 -22 -40 -63 -36 -56 -62 -42 -61 -36
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.65 3.11 3.28 2.51 3.38 4.48 1.13 2.70 1.72 4.19 7.04
Price to Tangible Book Value (P/TBV)		 2.65 3.11 3.28 2.51 3.38 4.48 1.13 2.70 1.72 4.19 7.04
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.05 0.06 0.03 0.00 0.30 0.25 0.08 0.10 0.13 0.21 0.34
Long-Term Debt to Equity		 0.05 0.06 0.03 0.00 0.30 0.19 0.08 0.10 0.00 0.21 0.00
Financial Leverage		 -1.08 -1.07 -1.06 -1.07 -1.13 -1.13 -1.04 -1.04 -1.06 -1.12 -1.22
Leverage Ratio		 1.19 1.15 1.13 1.10 1.27 1.48 1.19 1.16 1.22 1.33 1.53
Compound Leverage Factor		 1.20 1.15 1.13 1.08 1.25 1.54 1.23 1.15 1.07 1.23 1.47
Debt to Total Capital		 4.93% 5.73% 3.26% 0.00% 23.20% 20.23% 7.01% 9.49% 11.22% 17.47% 25.63%
Short-Term Debt to Total Capital		 0.30% 0.34% 0.28% 0.00% 0.00% 4.91% 0.00% 0.55% 11.22% 0.04% 25.63%
Long-Term Debt to Total Capital		 4.63% 5.39% 2.98% 0.00% 23.20% 15.33% 7.01% 8.94% 0.00% 17.43% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 95.07% 94.27% 96.74% 100.00% 76.80% 79.77% 92.99% 90.51% 88.78% 82.53% 74.37%
Debt to EBITDA		 -0.11 -0.07 -0.06 0.00 -0.23 -0.42 -0.28 -0.25 -0.36 -0.25 -0.42
Net Debt to EBITDA		 2.20 1.28 1.87 0.00 0.93 1.75 3.86 2.55 3.03 1.40 1.52
Long-Term Debt to EBITDA		 -0.10 -0.07 -0.05 0.00 -0.23 -0.32 -0.28 -0.24 0.00 -0.24 0.00
Debt to NOPAT		 -0.15 -0.10 -0.08 0.00 -0.33 -0.59 -0.39 -0.36 -0.51 -0.36 -0.62
Net Debt to NOPAT		 3.13 1.80 2.64 0.00 1.33 2.46 5.45 3.61 4.26 2.05 2.22
Long-Term Debt to NOPAT		 -0.14 -0.09 -0.08 0.00 -0.33 -0.45 -0.39 -0.34 0.00 -0.36 0.00
Altman Z-Score		 8.67 5.75 13.32 13.10 -1.91 2.30 3.66 5.28 0.68 -1.63 -3.56
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 13.28 10.93 13.11 11.18 5.82 6.69 19.77 11.78 6.64 5.59 2.58
Quick Ratio		 13.04 10.84 12.81 11.05 5.68 6.27 19.52 11.35 6.42 5.44 2.52
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -7.96 -13 -16 -23 -40 -33 -34 -45 -30 -35 -29
Operating Cash Flow to CapEx		 -10,812.66% -128,260.05% -77,639.90% -11,353.99% -472,077.09% 0.00% -545,169.19% -347,105.39% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -70.87 -119.08 -138.20 -155.44 -66.87 -17.33 -19.55 -26.55 -14.26 -18.09 -15.36
Operating Cash Flow to Interest Expense		 -82.91 -143.57 -169.43 -203.40 -74.50 -19.69 -24.43 -33.43 -14.64 -22.43 -17.50
Operating Cash Flow Less CapEx to Interest Expense		 -83.68 -143.68 -169.65 -205.19 -74.51 -19.69 -24.43 -33.44 -14.64 -22.43 -17.50
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.42 -1.95 -2.01 -6.98 -11 -3.26 -8.55 -7.46 -7.88 -15 -11
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.43 -0.52 -0.06 -4.97 -3.77 7.50 -5.30 1.09 -0.42 -7.23 4.57
Enterprise Value (EV)		 40 44 88 124 104 204 18 249 79 211 257
Market Capitalization		 66 67 130 218 162 266 232 408 206 297 312
Book Value per Share		 $2.56 $1.72 $2.07 $3.30 $1.72 $1.53 $3.54 $2.58 $2.04 $1.19 $0.74
Tangible Book Value per Share		 $2.56 $1.72 $2.07 $3.30 $1.72 $1.53 $3.54 $2.58 $2.04 $1.19 $0.74
Total Capital		 26 23 41 87 63 75 221 167 135 86 60
Total Debt		 1.29 1.32 1.34 0.00 15 15 16 16 15 15 15
Total Long-Term Debt		 1.21 1.24 1.22 0.00 15 11 16 15 0.00 15 0.00
Net Debt		 -26 -24 -42 -94 -59 -63 -214 -158 -128 -86 -55
Capital Expenditures (CapEx)		 0.09 0.01 0.02 0.26 0.01 0.00 0.01 0.02 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.54 -2.00 -2.22 -7.30 -11 -3.55 -8.81 -7.73 -2.13 -16 -11
Debt-free Net Working Capital (DFNWC)		 26 23 41 86 62 74 221 167 141 86 59
Net Working Capital (NWC)		 26 23 41 86 62 71 221 166 126 85 44
Net Nonoperating Expense (NNE)		 3.70 5.61 6.60 11 17 12 18 18 7.59 14 9.16
Net Nonoperating Obligations (NNO)		 -26 -24 -42 -94 -59 -63 -214 -158 -128 -86 -55
Total Depreciation and Amortization (D&A)		 0.05 0.33 0.19 -0.11 -0.24 0.53 0.67 0.54 0.60 -1.24 -0.68
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.40) ($1.65) ($1.40) ($1.79) ($2.24) ($1.11) ($1.07) ($1.06) ($0.64) ($0.94) ($0.56)
Adjusted Weighted Average Basic Shares Outstanding		 8.63M 15.13M 19.66M 27.40M 29.66M 47.25M 58.10M 58.41M 58.94M 59.48M 60.06M
Adjusted Diluted Earnings per Share		 ($1.40) ($1.65) ($1.40) ($1.79) ($2.24) ($1.11) ($1.07) ($1.06) ($0.64) ($0.94) ($0.56)
Adjusted Weighted Average Diluted Shares Outstanding		 8.63M 15.13M 19.66M 27.40M 29.66M 47.25M 58.10M 58.41M 58.94M 59.48M 60.06M
Adjusted Basic & Diluted Earnings per Share		 ($1.40) ($1.65) ($1.40) ($1.79) ($2.24) ($1.11) ($1.07) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 9.71M 11.35M 15.92M 21.69M 27.11M 33.97M 54.04M 58.58M 58.90M 59.71M 60.18M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.39 -13 -16 -28 -44 -25 -39 -44 -30 -42 -25
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -106.75 -177.20 -198.22 -270.44 -104.45 -19.13 -32.27 -37.00 -20.66 -31.21 -18.51
NOPAT to Interest Expense		 -74.73 -124.04 -138.75 -189.31 -73.12 -13.39 -22.59 -25.90 -14.46 -21.85 -12.96
EBIT Less CapEx to Interest Expense		 -107.52 -177.31 -198.44 -272.24 -104.47 -19.13 -32.28 -37.01 -20.66 -31.21 -18.51
NOPAT Less CapEx to Interest Expense		 -75.49 -124.15 -138.97 -191.10 -73.13 -13.39 -22.59 -25.91 -14.46 -21.85 -12.96
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.48% 0.00%

Quarterly Metrics And Ratios for Aldeyra Therapeutics

This table displays calculated financial ratios and metrics derived from Aldeyra Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding		 58,895,768.00 59,414,489.00 59,421,551.00 - 59,708,654.00 59,895,588.00 59,895,588.00 60,162,773.00 60,182,782.00 60,321,068.00 60,326,421.00
DEI Adjusted Shares Outstanding		 58,895,768.00 59,414,489.00 59,421,551.00 - 59,708,654.00 59,895,588.00 59,895,588.00 60,162,773.00 60,182,782.00 60,321,068.00 60,326,421.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.14 -0.28 -0.25 - -0.17 -0.16 -0.13 -0.11 -0.06 -0.09 -0.06
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 43.31% -81.11% -76.22% -184.11% -13.36% 43.12% 50.72% 61.05% 67.97% 44.88% 51.17%
EBIT Growth		 44.10% -74.11% -68.97% -171.87% -11.00% 43.53% 50.42% 59.78% 65.98% 42.47% 48.30%
NOPAT Growth		 44.10% -74.11% -68.97% -171.87% -11.00% 43.53% 50.42% 59.78% 65.98% 42.47% 48.30%
Net Income Growth		 48.24% -87.47% -84.60% -232.61% -22.86% 42.03% 49.13% 59.13% 65.23% 44.20% 51.06%
EPS Growth		 48.15% -86.67% -78.57% -237.50% -21.43% 42.86% 48.00% 62.96% 64.71% 43.75% 53.85%
Operating Cash Flow Growth		 -5.60% 1.00% 0.62% -2,505.25% -25.04% 35.31% 11.96% 55.97% 59.02% 46.36% 41.26%
Free Cash Flow Firm Growth		 -33.70% -37.06% 68.19% -13.68% 97.49% 79.18% -126.86% -111.43% -1,692.03% -246.80% -12.37%
Invested Capital Growth		 62.80% -17.49% -193.87% -91.78% -157.43% -69.38% 12.25% 30.26% 33.58% 37.26% 47.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -58.49% -95.13% 10.24% -2.35% 36.76% 2.09% 22.24% 19.10% 48.00% -68.51% 31.11%
EBIT Q/Q Growth		 -54.05% -91.70% 10.39% -2.73% 37.10% 2.48% 21.32% 16.66% 46.81% -64.95% 29.30%
NOPAT Q/Q Growth		 -54.05% -91.70% 10.39% -2.73% 37.10% 2.48% 21.32% 16.66% 46.81% -64.95% 29.30%
Net Income Q/Q Growth		 -70.04% -108.45% 10.30% -4.60% 37.19% 1.63% 21.29% 15.96% 46.57% -57.86% 30.96%
EPS Q/Q Growth		 -75.00% -100.00% 10.71% -8.00% 37.04% 5.88% 18.75% 23.08% 40.00% -50.00% 33.33%
Operating Cash Flow Q/Q Growth		 -2,092.78% -32.61% 39.70% -50.93% -3.60% 31.39% 17.93% 24.53% 3.57% 10.19% 10.13%
Free Cash Flow Firm Q/Q Growth		 -264.77% 17.32% 72.95% -39.35% 91.96% -587.00% -194.71% -29.87% 31.85% -32.95% 4.51%
Invested Capital Q/Q Growth		 44.01% -53.61% -82.45% -22.21% 24.84% -1.07% 5.48% 2.88% 28.42% 4.52% 20.15%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 86.04% 93.56% 93.65% 95.36% 95.22% 96.05% 96.09% 96.90% 97.34% 93.16% 90.97%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -23.94% -33.19% -43.05% -58.54% -65.19% -65.91% -64.31% -58.73% -51.76% -49.48% -45.29%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -23.94% -33.19% -43.05% -58.54% -65.19% -65.91% -64.31% -58.73% -51.76% -49.48% -45.29%
Return on Equity Simple (ROE_SIMPLE)		 -26.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.58 -13 -11 -12 -7.30 -7.12 -5.60 -4.67 -2.48 -4.10 -2.90
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.13% -3.52% -3.40% -3.93% -2.73% -3.08% -2.65% -2.55% -1.56% -2.42% -1.72%
Return On Investment Capital (ROIC_SIMPLE)		 -5.11% -11.10% -11.25% -13.49% -9.28% -10.11% -8.69% -7.84% -4.32% -10.81% -8.22%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -9.39 -18 -16 -17 -10 -10 -8.00 -6.67 -3.55 -5.85 -4.14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.45 -18 -17 -17 -11 -10 -8.15 -6.60 -3.43 -5.78 -3.98
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.70 2.00 3.76 4.19 5.40 4.15 6.35 7.04 2.41 3.39 2.11
Price to Tangible Book Value (P/TBV)		 1.70 2.00 3.76 4.19 5.40 4.15 6.35 7.04 2.41 3.39 2.11
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.13 0.16 0.18 0.21 0.24 0.27 0.31 0.34 0.36 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.18 0.21 0.24 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.06 -1.06 -1.08 -1.12 -1.09 -1.12 -1.17 -1.22 -1.18 -1.20 -1.20
Leverage Ratio		 1.23 1.23 1.27 1.33 1.32 1.37 1.45 1.53 1.51 1.42 1.43
Compound Leverage Factor		 1.06 1.15 1.19 1.26 1.26 1.32 1.40 1.49 1.47 1.32 1.31
Debt to Total Capital		 11.82% 13.42% 15.22% 17.47% 19.19% 21.51% 23.59% 25.63% 26.63% 0.00% 0.00%
Short-Term Debt to Total Capital		 11.82% 13.42% 0.28% 0.04% 0.00% 21.51% 23.59% 25.63% 26.63% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 14.94% 17.43% 19.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 88.18% 86.58% 84.78% 82.53% 80.81% 78.49% 76.41% 74.37% 73.37% 100.00% 100.00%
Debt to EBITDA		 -0.43 -0.35 -0.30 -0.25 -0.24 -0.28 -0.33 -0.42 -0.53 0.00 0.00
Net Debt to EBITDA		 3.37 2.43 1.93 1.40 1.20 1.22 1.30 1.52 1.73 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 -0.30 -0.24 -0.24 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.61 -0.51 -0.44 -0.36 -0.35 -0.41 -0.48 -0.62 -0.77 0.00 0.00
Net Debt to NOPAT		 4.76 3.49 2.81 2.05 1.75 1.79 1.90 2.22 2.50 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 -0.43 -0.36 -0.35 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.95 0.06 1.35 -0.26 0.69 -2.72 -1.61 -2.25 -7.17 -5.98 -9.92
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.50 4.55 6.80 5.59 6.49 2.86 2.72 2.58 2.72 4.91 5.45
Quick Ratio		 6.14 4.36 6.57 5.44 6.30 2.77 2.64 2.52 2.67 4.67 5.20
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -14 -12 -3.14 -4.37 -0.35 -2.41 -7.12 -9.24 -6.30 -8.37 -8.00
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -28.13 -24.28 -6.54 -9.28 -0.73 -5.13 -14.95 -19.44 -13.44 -364,064.00 -18,256.06
Operating Cash Flow to Interest Expense		 -20.00 -27.69 -16.64 -25.56 -25.79 -18.18 -14.75 -11.15 -10.90 -199,540.09 -9,416.66
Operating Cash Flow Less CapEx to Interest Expense		 -20.00 -27.69 -16.64 -25.56 -25.79 -18.18 -14.75 -11.15 -10.90 -199,540.09 -9,416.66
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -4.41 -6.78 -12 -15 -11 -11 -11 -11 -7.55 -7.20 -5.75
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 7.45 -1.01 -8.16 -7.23 -6.95 -4.70 1.52 4.57 3.82 4.28 5.10
Enterprise Value (EV)		 75 92 223 211 268 163 253 257 52 83 33
Market Capitalization		 193 197 320 297 343 229 313 312 102 128 74
Book Value per Share		 $1.93 $1.65 $1.43 $1.19 $1.06 $0.92 $0.82 $0.74 $0.70 $0.63 $0.58
Tangible Book Value per Share		 $1.93 $1.65 $1.43 $1.19 $1.06 $0.92 $0.82 $0.74 $0.70 $0.63 $0.58
Total Capital		 129 114 100 86 79 70 64 60 57 38 35
Total Debt		 15 15 15 15 15 15 15 15 15 0.00 0.00
Total Long-Term Debt		 0.00 0.00 15 15 15 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -118 -105 -97 -86 -75 -67 -60 -55 -50 -45 -41
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 1.34 -7.03 -13 -16 -12 -12 -11 -11 -7.75 -7.37 -5.94
Debt-free Net Working Capital (DFNWC)		 134 113 100 86 78 70 64 59 57 38 35
Net Working Capital (NWC)		 119 98 100 85 78 55 49 44 42 38 35
Net Nonoperating Expense (NNE)		 1.51 4.24 3.82 4.20 2.63 2.65 2.09 1.79 0.97 1.35 0.87
Net Nonoperating Obligations (NNO)		 -118 -105 -97 -86 -75 -67 -60 -55 -50 -45 -41
Total Depreciation and Amortization (D&A)		 -0.05 -0.43 -0.41 -0.36 -0.28 -0.32 -0.15 0.07 0.12 0.07 0.15
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.14) ($0.28) ($0.25) ($0.27) ($0.17) ($0.16) ($0.13) ($0.10) ($0.06) ($0.09) ($0.06)
Adjusted Weighted Average Basic Shares Outstanding		 59.41M 59.41M 59.53M 59.48M 59.89M 60.05M 60.13M 60.06M 60.32M 60.32M 60.35M
Adjusted Diluted Earnings per Share		 ($0.14) ($0.28) ($0.25) ($0.27) ($0.17) ($0.16) ($0.13) ($0.10) ($0.06) ($0.09) ($0.06)
Adjusted Weighted Average Diluted Shares Outstanding		 59.41M 59.41M 59.53M 59.48M 59.89M 60.05M 60.13M 60.06M 60.32M 60.32M 60.35M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 59.41M 59.42M 59.55M 59.71M 59.90M 59.90M 60.16M 60.18M 60.32M 60.33M 60.36M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.58 -13 -11 -12 -7.30 -7.12 -5.60 -4.67 -2.48 -4.10 -2.90
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -18.84 -37.70 -33.67 -35.21 -21.57 -21.61 -16.81 -14.03 -7.57 -254,369.87 -9,443.55
NOPAT to Interest Expense		 -13.19 -26.39 -23.57 -24.65 -15.10 -15.13 -11.77 -9.82 -5.30 -178,058.91 -6,610.48
EBIT Less CapEx to Interest Expense		 -18.84 -37.70 -33.67 -35.21 -21.57 -21.61 -16.81 -14.03 -7.57 -254,369.87 -9,443.55
NOPAT Less CapEx to Interest Expense		 -13.19 -26.39 -23.57 -24.65 -15.10 -15.13 -11.77 -9.82 -5.30 -178,058.91 -6,610.48
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -0.48% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Aldeyra Therapeutics’ financial statements show a company still in development mode, with no reported product revenue and continued operating losses. However, quarterly losses and operating cash burn have generally improved from the elevated levels seen in 2024, while the company eliminated its short-term debt during the second quarter of 2026.

  • Debt was eliminated. Short-term debt declined from $15.3 million at the end of the first quarter of 2026 to zero at June 30, 2026. Aldeyra also reported no long-term debt, strengthening its balance sheet and reducing future interest obligations.
  • Quarterly operating losses remain below 2024 levels. The Q2 2026 net loss was $5.5 million, compared with losses of $8.1 million in Q1 2024, $16.8 million in Q2 2024 and $15.1 million in Q3 2024. This suggests better cost control, although the loss increased from $3.5 million in Q1 2026.
  • Research and development spending has moderated. R&D expense was $3.5 million in Q2 2026, down from $8.5 million in Q2 2025 and $15.0 million in Q2 2024. Lower spending could extend the company’s cash runway, though it may also reflect changes in development activity.
  • Interest income continues to partially offset operating costs. Aldeyra generated $400,257 of interest and investment income in Q2 2026, while interest expense was only $23. Interest income has helped reduce losses throughout the reported period as the company invested its cash reserves.
  • Liquidity remains adequate in the near term. Cash and equivalents totaled $45.1 million at June 30, 2026, compared with $65.0 million at March 31, 2026. Based on Q2 operating cash burn of $4.6 million, the reported cash balance represents roughly nine quarters of operating funding before considering changes in spending, financing or clinical costs.
  • The company has no meaningful revenue base yet. Revenue was reported as zero in each provided income statement, leaving Aldeyra dependent on cash reserves, financing, potential partnerships and eventual product commercialization.
  • Operating cash flow remains consistently negative. Aldeyra used $4.6 million in operating cash during Q2 2026 and $5.1 million in Q1 2026. Operating cash flow was also negative in every provided quarter from Q2 2024 through Q4 2025, demonstrating that the business is not yet self-funding.
  • Cash reserves have fallen sharply over the longer term. Cash and equivalents declined from $143.3 million in Q3 2023 and $102.5 million in Q1 2024 to $45.1 million in Q2 2026. Total assets fell from $147.3 million in Q3 2023 to $47.5 million, highlighting the effect of sustained losses and investment spending.
  • Q2 cash flow was pressured by financing activity. Net cash fell by $19.9 million in Q2 2026, including a $15.3 million financing outflow associated with debt repayment. Although this reduced leverage, it accelerated the decline in cash during the quarter.
  • Accumulated losses remain substantial. Retained earnings were negative $492.9 million at June 30, 2026, compared with negative $389.5 million in Q3 2023. Continued losses could require future capital raises, potentially diluting existing shareholders.

Overall, Aldeyra’s balance sheet is less leveraged and its quarterly spending is lower than it was in 2024, which are constructive developments. Nevertheless, the company continues to report no revenue, negative operating cash flow and a shrinking cash balance. Investors should closely monitor clinical progress, future financing needs and whether R&D spending can eventually produce a commercial product.

11/14/26 07:54 PM ETAI Generated. May Contain Errors.

Aldeyra Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Aldeyra Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Aldeyra Therapeutics' net income appears to be on a downward trend, with a most recent value of -$33.85 million in 2025, falling from -$12.09 million in 2015. The previous period was -$55.85 million in 2024. Find out what analysts predict for Aldeyra Therapeutics in the coming months.

Aldeyra Therapeutics' total operating income in 2025 was -$35.27 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $35.27 million

Over the last 10 years, Aldeyra Therapeutics' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

In the past 12 quarters, Aldeyra Therapeutics' cash and equivalents has ranged from $40.97 million in Q3 2026 to $143.33 million in Q3 2023, and is currently $40.97 million as of their latest financial filing in Q3 2026.

Aldeyra Therapeutics had total debt of $15.25 million at the end of 2025, a 1.5% increase from 2024, and a 1,083.2% increase since 2015.

Over the last 10 years, Aldeyra Therapeutics' book value per share changed from 2.56 in 2015 to 0.74 in 2025, a change of -71.3%.


Related Companies

Financial statements for NASDAQ:ALDX last updated on 11/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The Democrats can’t stop this
Porter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...
Porter & Company | Sponsoredtc pixel
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...
Behind the Markets | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...
Weiss Ratings | Sponsoredtc pixel
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...
Paradigm Press | Sponsoredtc pixel
Management just bought 2.8 million shares
Management just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...
Monument Traders Alliance | Sponsoredtc pixel
Elon wants to move AI off the planet. Amazon isn't ready.
What if the next AI race isn't on Earth? Tim Bohen's Mission X presentation explores Elon Musk's idea of movin...
StocksToTrade | Sponsoredtc pixel